New Hope Network is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Aker BioMarine Science Board explores future of krill

Aker BioMarine Science Board explores future of krill
Scientific experts convened in Oslo, Norway, to discuss the commercial opportunities and regulatory issues surrounding krill.

The Aker BioMarine Science Board (ASB), made up of recognized scientific experts, met last week in Oslo, Norway to discuss the commercial and regulatory landscape for krill phospholipid omega-3s and the global demands for increased omega-3 consumption and supplementation. Given the international scope of Aker BioMarine Antarctic's business, each member of the ASB will provide guidance to the company from diverse complementary disciplines as well as from different geographical regions. 


In his welcome address to the ASB, Aker CEO Hallvard Muri thanked the attendees for their participation: "As esteemed researchers, scientists, and professors, you each are fully scheduled with important work. We are grateful that you have chosen to spend time together with us and our scientists in order to identify the future direction for our development program and investments in krill-derived products for human and animal health."


 Aker Biomarine Antarctic is a young company, established in 2006. In under 5 years, the company has been recognized as providing vital health supplements. "Our investments in serious scientific research and documentation have been of major importance in how we consciously have built Aker BioMarine as a serious industry player," Mr. Muri added.


The Aker Science Board will provide strategic guidance for ongoing research and development including in vitro, preclinical and clinical studies as well as the development of supplements and products for the food and beverage, cosmetics, and feed categories internationally.


Founding Board Members include: Dr. Sebastiano Banni, Associate Professor of Physiology at the Faculty of Sciences for the University of Cagliari; Professor Philip Calder, President of the International Society for the Study of Fatty Acids and Lipids (ISSFAL); Dr. Vincenzo Di Marzo, Research Director at the Institute of Biomolecular Chemistry of the National Research Council in Pozzuoli, Naples, Italy; Dr.Tomohito Hamazaki, past president and chair of the board of Japan Society for Lipid Nutrition; Dr. William Harris, PhD in Nutritional Biochemistry from the University of Minnesota, Director of Research and Clinical Trials at Health Diagnostic Laboratory, Inc. (Richmond, VA, USA); Mr. Willem van Nieuwenhuyzen, Ir. (MSc.) degree in Food Science and Technology from Wageningen University (the Netherlands).


"This meeting has given me new knowledge about omega-3 phospholipids and their potential health benefits," says William Harris.  "In this first ASB meeting we discussed the existing data behind krill oil and omega-3 phospholipids, and we reviewed the designs and progress of ongoing clinical trials with Superba Krill Oil.  These new data will help clarify the role that krill oil may be able to play in improving human health."


"I am impressed about the structured approach to the documentation work on Superba Krill Oil presented by Aker BioMarine to ASB" says Professor Philip Calder.  "I am looking forward to future discussions and interpretation of new scientific and clinical data from Superba Krill Oil on biological health benefits."


Aker BioMarine Antarctic is the only krill ingredient marketer that is primary in its supply. Aker BioMarine Antarctic's proprietary Eco-Harvesting(TM) technology and on-board processing result in the unique composition of Superba(TM) Krill Oil and provide full traceability from sea to shelf.  The Marine Stewardship Council (MSC) has granted MSC Certification to Aker BioMarine Antarctic's fisheries, an exclusive distinction that no other krill fishery has earned. As part of an established commitment to substantiating krill's health benefits, Aker BioMarine Antarctic continues to sponsor in vitro, in vivo, and human clinical trials with phospholipid EPA & DHA from krill oil, consistently demonstrating a higher uptake of phospholipid omega-3 fatty acids, improved blood lipid profiles, and increased uptake of DHA in brain tissue compared to other omega-3 fatty acid sources.  


About SuperbaTM Krill Oil

Superba(TM) Krill Oil is a pure, natural source of the health-promoting EPA & DHA omega-3 essential fatty acids and the naturally occurring antioxidant astaxanthin. The uniqueness of SuperbaTM Krill Oil is that the omega-3 fatty acids are provided in phospholipid form.  In vitro, in vivo and human clinical research has demonstrated the safety and efficacy of SuperbaTM Krill Oil.


About Aker BioMarine Antarctic

Aker BioMarine Antarctic is an integrated biotechnology company dedicated to the sustainable harvesting of krill and development of krill-derived biotech products. The company supplies biomarine ingredients through an optimized value chain from raw materials to customers. Aker BioMarine Antarctic's SuperbaTM Krill products are provided with 100% traceability from the Antarctic sea to the end user.  Only Aker's krill fishery has been awarded Marine Stewardship Council (MSC) Certification.


Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.